Avadel Pharmaceuticals (AVDL) Stock Statistics & Valuation Metrics

Avadel Pharmaceuticals has a market cap or net worth of $2.11B. The enterprise value is $2.07B.

Avadel Pharmaceuticals has 97,817,590 shares outstanding. The number of shares has decreased by -2.65% in one year.

Avadel Pharmaceuticals’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -36.37%.

The current PE Ratio of Avadel Pharmaceuticals is ―. Avadel Pharmaceuticals’s PEG ratio is 0.27.

In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M and earned -48.83M in profits. Earnings per share was -0.51.

In the last 12 months, operating cash flow was 35.60M and capital expenditures -191.76K, giving a free cash flow of 35.41M billion.

Avadel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Avadel Pharmaceuticals upcoming earnings date is Mar 9, 2026, Before Open (Confirmed).

Avadel Pharmaceuticals as a current ratio of 2.75, with Debt / Equity ratio of 38.05%

In the past 12 months, Avadel Pharmaceuticals has paid -247.00K in taxes.

Avadel Pharmaceuticals EV to EBITDA ratio is -26.72, with an EV/FCF ratio of -20.26.

Avadel Pharmaceuticals has $91.58M in cash and marketable securities with $37.38M in debt, giving a net cash position of $54.20M billion.

Gross margin is 94.47%, with operating margin of -25.07%, and net profit margin of -28.87%.

The average price target for Avadel Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―